Skip to content

13F-HR filed by Aquilo Capital Management, LLC

Aquilo Capital Management, LLC filed this 13F-HR for the quarter ended 2019-09-30, filed 2019-11-14, with 11 holding rows worth $141,999,000.

Accession
0001591986-19-000010
Filed
2019-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2019

A holdings report, 11 entries on the cover page, a total value of $141,999,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $141,999,000 with VALUE read as thousands by filing date, 13F file number 028-18892. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SPDR SER TR78464A870S&P BIOTECH500,000$38,125,000thousands by filing dateput
MERUS N VN5749R100COM1,038,746$18,510,000thousands by filing date
UNIQURE NVN90064101SHS400,000$15,744,000thousands by filing datecall
UNIQURE NVN90064101SHS391,199$15,398,000thousands by filing date
SPERO THERAPEUTICS INC84833T103COM1,154,356$12,236,000thousands by filing date
PIERIS PHARMACEUTICALS INC720795103COM2,958,243$10,088,000thousands by filing date
BICYCLE THERAPEUTICS PLC-ADR088786108SPONSORED ADS767,026$8,736,000thousands by filing date
LAKEFRONT BIOTHERAPEUTICS NV36315X101SPON ADR56,840$8,677,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock951,527$8,573,000thousands by filing date
PROQR THERAPEUTICS NVN71542109SHS EURO831,661$4,790,000thousands by filing date
FATE THERAPEUTICS INC31189P102COM72,273$1,122,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001591986-19-000010this filing2019-11-14acceptance time not in the bulk data set